Pyxis Oncology, Inc.
PYXSHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. The company carries a $324.5M market cap, placing it firmly in the small-cap category. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.
Market Cap
$324.5M
Beta
1.34
P/E (TTM)
—
P/E (Fwd)
-3.45
EPS (TTM)
$-1.40
EPS (Fwd)
$-1.13
ROE
-179.1%
ROA
-62.9%
Cash
$33.0M
Total Debt
$17.8M
Free CF
-$23.2M
52W Change
108.0%
Annual Financials
Cash vs Debt
Where PYXS stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, PYXS finished 79.43% above its 150-day moving average ($2.09) and 64.47% above its 200-day moving average ($2.28). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PYXS overbought or oversold?
At the September 3, 2026 close, PYXS's RSI(14) was 70.1, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $33.0M in cash and $17.8M in debt, PYXS maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$23.2M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -179.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing PYXS.